BR112017011771A2 - métodos e composições para o tratamento de câncer - Google Patents

métodos e composições para o tratamento de câncer

Info

Publication number
BR112017011771A2
BR112017011771A2 BR112017011771A BR112017011771A BR112017011771A2 BR 112017011771 A2 BR112017011771 A2 BR 112017011771A2 BR 112017011771 A BR112017011771 A BR 112017011771A BR 112017011771 A BR112017011771 A BR 112017011771A BR 112017011771 A2 BR112017011771 A2 BR 112017011771A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
cancer treatment
cancer
treatment
Prior art date
Application number
BR112017011771A
Other languages
English (en)
Portuguese (pt)
Inventor
Sampath Prakash
P Junghans Richard
Sengupta Sadhak
Original Assignee
Prospect Chartercare Rwmc Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prospect Chartercare Rwmc Llc filed Critical Prospect Chartercare Rwmc Llc
Publication of BR112017011771A2 publication Critical patent/BR112017011771A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112017011771A 2014-12-02 2015-12-01 métodos e composições para o tratamento de câncer BR112017011771A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086346P 2014-12-02 2014-12-02
PCT/US2015/063267 WO2016089916A1 (en) 2014-12-02 2015-12-01 Methods and compositons for treating cancer

Publications (1)

Publication Number Publication Date
BR112017011771A2 true BR112017011771A2 (pt) 2018-07-10

Family

ID=56078487

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011771A BR112017011771A2 (pt) 2014-12-02 2015-12-01 métodos e composições para o tratamento de câncer

Country Status (18)

Country Link
US (2) US9650428B2 (enExample)
EP (1) EP3227317A4 (enExample)
JP (1) JP2017537622A (enExample)
KR (1) KR20180041087A (enExample)
CN (1) CN107709353A (enExample)
AR (1) AR102879A1 (enExample)
AU (1) AU2015355084A1 (enExample)
BR (1) BR112017011771A2 (enExample)
CA (1) CA2969714A1 (enExample)
EA (1) EA201791210A1 (enExample)
HK (1) HK1251862A1 (enExample)
IL (1) IL252610A0 (enExample)
MX (1) MX2017007272A (enExample)
PH (1) PH12017501031A1 (enExample)
SG (2) SG10202103475XA (enExample)
TW (1) TW201636425A (enExample)
UY (1) UY36418A (enExample)
WO (1) WO2016089916A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112871A1 (en) 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic il-13 polypeptides
US9738696B2 (en) 2012-08-09 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
EP3653212B1 (en) 2012-12-20 2023-04-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
WO2016089916A1 (en) 2014-12-02 2016-06-09 Roger Williams Hospital Methods and compositons for treating cancer
FI3909972T3 (fi) * 2015-06-19 2024-05-03 Sebastian Kobold Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä
EP3575403A1 (en) * 2015-08-05 2019-12-04 Yoo Young Pharm Co., Ltd. Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
WO2018112266A1 (en) * 2016-12-14 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
AU2018347796B2 (en) 2017-10-10 2025-07-24 Medicenna Therapeutics, Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
KR20200100654A (ko) * 2017-11-20 2020-08-26 프로스펙트 차터케어 알더블유엠씨, 엘엘씨 디/비/에이 로저 윌리암스 메디컬 센터 Car-t 세포 기능성을 개선하기 위한 조성물 및 그의 용도
CN112218885B (zh) 2017-12-20 2024-06-18 波赛达治疗公司 Vcar组合物和使用方法
AU2019209428B2 (en) 2018-01-22 2025-06-26 Endocyte, Inc. Methods of use for CAR T cells
EP3743445A1 (en) * 2018-01-26 2020-12-02 City of Hope Chimeric antigen receptors and methods for reducing off target toxicity
CA3090089A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CN110144326A (zh) * 2018-02-12 2019-08-20 深圳宾德生物技术有限公司 一种靶向性抗肿瘤t细胞及其制备方法和应用
CN110157674A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
CN108440674A (zh) * 2018-04-28 2018-08-24 杭州荣泽生物科技有限公司 一种Trop-2特异性嵌合抗原受体细胞制备及其用途
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
US12419954B2 (en) * 2020-01-31 2025-09-23 City Of Hope Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies
EP4100428A4 (en) 2020-02-04 2024-03-06 Seattle Children's Hospital (DBA Seattle Children's Research Institute) CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS
JP2023539871A (ja) * 2020-08-26 2023-09-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グリア芽細胞腫を処置するための方法および組成物
EP4210727A4 (en) * 2020-09-11 2024-12-25 University of Georgia Research Foundation, Inc. COMPOSITIONS AND METHODS OF USE THEREOF FOR PREVENTING AND TREATING INFLUENZA INFECTIONS
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
CN114907485B (zh) * 2021-02-08 2024-04-26 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN113304267B (zh) * 2021-06-11 2022-03-15 河南大学 肺癌的治疗靶点及其应用
CN114014941B (zh) * 2022-01-10 2022-04-12 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN116549667B (zh) * 2023-05-29 2024-02-09 四川普锐特药业有限公司 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965126A (en) * 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
JP2004500047A (ja) * 1999-10-20 2004-01-08 ザ　ジョンズ　ホプキンス　ユニバーシティー　スクール　オブ　メディシン キメラ免疫原性組成物およびこれらをコードする核酸
JP2005518800A (ja) * 2002-03-01 2005-06-30 ブリストル−マイヤーズ　スクイブ　カンパニー 構成的に活性化されたチロシンキナーゼレセプターを発現するトランスジェニック非ヒト哺乳動物
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
US7709625B2 (en) * 2004-06-10 2010-05-04 The Board Of Regents Of The University Of Texas Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy
CA2630334C (en) * 2005-11-16 2013-07-23 Universidad Nacional Autonoma De Mexico Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
CN101616685B (zh) * 2006-03-06 2013-07-24 阿穆尼克斯运营公司 非结构化重组聚合物和其应用
US20080206139A1 (en) * 2006-11-03 2008-08-28 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
EP4032552B1 (en) * 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US9273283B2 (en) * 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
CA2793753C (en) * 2010-03-26 2018-06-05 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
EP2931893A1 (en) * 2012-12-13 2015-10-21 Universität Leipzig T-cell modulation by exon skipping
PT3613439T (pt) * 2013-02-15 2021-05-12 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
WO2014164554A1 (en) * 2013-03-10 2014-10-09 Baylor College Of Medicine Chemotherapy-resistant immune cells
EP3105333B1 (en) * 2014-02-10 2020-04-08 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
WO2016089916A1 (en) 2014-12-02 2016-06-09 Roger Williams Hospital Methods and compositons for treating cancer

Also Published As

Publication number Publication date
CN107709353A (zh) 2018-02-16
TW201636425A (zh) 2016-10-16
US20160151490A1 (en) 2016-06-02
EP3227317A4 (en) 2018-04-25
AR102879A1 (es) 2017-03-29
AU2015355084A1 (en) 2017-06-29
WO2016089916A1 (en) 2016-06-09
PH12017501031A1 (en) 2017-11-27
US9650428B2 (en) 2017-05-16
KR20180041087A (ko) 2018-04-23
SG10202103475XA (en) 2021-05-28
CA2969714A1 (en) 2016-06-09
EP3227317A1 (en) 2017-10-11
UY36418A (es) 2016-06-30
EA201791210A1 (ru) 2017-11-30
SG11201704519YA (en) 2017-07-28
MX2017007272A (es) 2018-06-06
JP2017537622A (ja) 2017-12-21
IL252610A0 (en) 2017-07-31
HK1251862A1 (zh) 2019-04-26
US20180072789A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL304820A (en) Preparations and methods for the treatment of cancer
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
IL255261A0 (en) Methods for treating cancer
PT3377516T (pt) Composição para o tratamento do cancro
IL256025A (en) Methods of diagnosing and treating cancer
LT3119808T (lt) Antikūnų kompozicijos vėžio gydymui
IL249065A0 (en) Combination therapies for the treatment of cancer
BR112017008399A2 (pt) abordagem de imunoterapia de combinação para tratamento de câncer
PT3283527T (pt) Terapêutica de combinação para o cancro
BR112015028115A2 (pt) métodos e composições para o tratamento de câncer
HUE053485T2 (hu) Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
HUE054673T2 (hu) Rák kezelésére szolgáló eljárások és készítmények
HUE038541T2 (hu) Rák kezelési módszerek
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
HUE054204T2 (hu) Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez
IL256523A (en) Compositions and methods for treating cancer
BR112016022976A2 (pt) Métodos para o tratamento de hcv
HUE040167T2 (hu) Rákkezelés
IL255638A (en) Compositions and methods for treating cancer
IL246558A0 (en) Novel methods for treating cancer
EP4043567C0 (en) METHOD AND COMPOSITIONS FOR TREATMENT OF CANCER
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
EP3161853C0 (en) PARTICLE BEAM PROCESSING
DK3407909T5 (da) Cancerbehandling

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements